Absci (ABSI) Set to Announce Earnings on Tuesday

Absci (NASDAQ:ABSI) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Absci (NASDAQ:ABSI) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The firm had revenue of $1.27 million for the quarter, compared to the consensus estimate of $2.05 million. Absci had a negative return on equity of 44.24% and a negative net margin of 2,838.89%. During the same period in the prior year, the company posted ($0.27) earnings per share. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Absci Stock Performance

Shares of ABSI opened at $4.07 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.49 and a quick ratio of 6.49. Absci has a one year low of $1.18 and a one year high of $6.72. The company’s fifty day moving average price is $3.99 and its 200 day moving average price is $4.09. The company has a market capitalization of $462.19 million, a PE ratio of -4.38 and a beta of 2.18.

Wall Street Analysts Forecast Growth

ABSI has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Absci in a report on Thursday, August 15th. Guggenheim assumed coverage on shares of Absci in a report on Wednesday, October 2nd. They issued a “buy” rating and a $10.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Absci has an average rating of “Buy” and an average target price of $8.67.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.